Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04116658 · ClinicalTrials.gov registry record · Phase 1
First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma
A Phase 1 study, sponsored by Enterome.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT04116658 is a Phase 1 study that has completed, run by Enterome. The registered enrollment target is 100 participants.
The verdict
NCT04116658, a Phase 1 study, has completed, sponsored by Enterome.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma.
Interventions
- BIOLOGICAL Multiple dose of EO2401
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-07-13 |
| Est. Completion | 2024-03-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04116658
The ClinicalTrials.gov registry entry for NCT04116658 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enterome, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Multiple dose of EO2401 is the first listed.
NCT04116658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04116658 about?
NCT04116658 is a clinical study titled "First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma". The purpose of this study is to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma.
What is the current status of trial NCT04116658?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2020-07-13. Estimated completion is 2024-03-04.
What interventions are being tested in trial NCT04116658?
The interventions under investigation include: Multiple dose of EO2401 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04116658?
This trial is sponsored by Enterome, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.